ABBOTT LABORATORIES Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31)
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) of -$48.29 million for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease · last filed 2012-11-07
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2012-09-30 was -$48.29M, a 234.31% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $1.43M, a 79.81% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$42.61M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $139.09M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2011 was $83.20M, a 35.34% decline from fiscal 2010.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2010 was $128.68M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2009 was -$24.87M.
- ABBOTT LABORATORIES other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2008 was -$2.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 3 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 6 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 9 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 12 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2012-09-30 | -$48.29M 10-Q · filed 2012-11-07 | -$46.86M derived: sum of 2 quarters · filed 2012-11-07 | -$89.47M 10-Q · filed 2012-11-07 | $49.62M derived: sum of 4 quarters · filed 2012-11-07 | ||||
| 2012-06-30 | $1.43M 10-Q · filed 2012-08-07 | -$41.18M 10-Q · filed 2012-08-07 | $97.91M derived: sum of 3 quarters · filed 2012-08-07 | $133.86M derived: sum of 4 quarters · filed 2012-11-07 | ||||
| 2012-03-31 | -$42.61M 10-Q · filed 2012-05-08 | $96.48M derived: sum of 2 quarters · filed 2012-05-08 | $132.43M derived: sum of 3 quarters · filed 2012-11-07 | $139.51M derived: sum of 4 quarters · filed 2012-11-07 | ||||
| 2011-12-31 | $139.09M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $175.04M derived: sum of 2 quarters · filed 2012-11-07 | $182.12M derived: sum of 3 quarters · filed 2012-11-07 | $83.20M 10-K · filed 2012-02-21 | ||||
| 2011-09-30 | $35.95M 10-Q · filed 2012-11-07 | $36.00M 10-Q · filed 2011-11-04 | $43.03M derived: sum of 2 quarters · filed 2012-11-07 | -$55.89M 10-Q · filed 2012-11-07 | -$56.00M 10-Q · filed 2011-11-04 | -$99.21M derived: sum of 4 quarters · filed 2012-11-07 | ||
| 2011-06-30 | $7.08M 10-Q · filed 2012-08-07 | $6.00M 10-Q · filed 2011-08-04 | -$91.84M 10-Q · filed 2012-08-07 | -$93.00M 10-Q · filed 2011-08-04 | -$135.16M derived: sum of 3 quarters · filed 2012-08-07 | -$165.16M derived: sum of 4 quarters · filed 2012-08-07 | ||
| 2011-03-31 | -$98.92M 10-Q · filed 2012-05-08 | -$99.00M 10-Q · filed 2011-05-06 | -$142.24M derived: sum of 2 quarters · filed 2012-05-08 | -$172.24M derived: sum of 3 quarters · filed 2012-05-08 | -$107.24M derived: sum of 4 quarters · filed 2012-05-08 | |||
| 2010-12-31 | -$43.32M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | -$73.32M derived: sum of 2 quarters · filed 2012-02-21 | -$8.32M derived: sum of 3 quarters · filed 2012-02-21 | $128.68M 10-K · filed 2012-02-21 | $129.00M 10-K · filed 2011-02-18 | |||
| 2010-09-30 | -$30.00M 10-Q · filed 2011-11-04 | $35.00M derived: sum of 2 quarters · filed 2011-11-04 | $172.00M 10-Q · filed 2011-11-04 | $182.13M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $65.00M 10-Q · filed 2011-08-04 | $202.00M 10-Q · filed 2011-08-04 | $212.13M derived: sum of 3 quarters · filed 2012-02-21 | $217.13M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $137.00M 10-Q · filed 2011-05-06 | $147.13M derived: sum of 2 quarters · filed 2012-02-21 | $152.13M derived: sum of 3 quarters · filed 2012-02-21 | $103.13M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2009-12-31 | $10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $15.13M derived: sum of 2 quarters · filed 2012-02-21 | -$33.87M derived: sum of 3 quarters · filed 2012-02-21 | -$24.87M 10-K · filed 2012-02-21 | -$24.00M 10-K · filed 2011-02-18 | |||
| 2009-09-30 | $5.00M 10-Q · filed 2010-11-05 | -$44.00M derived: sum of 2 quarters · filed 2010-11-05 | -$35.00M 10-Q · filed 2010-11-05 | |||||
| 2009-06-30 | -$49.00M 10-Q · filed 2010-08-05 | -$40.00M 10-Q · filed 2010-08-05 | ||||||
| 2008-12-31 | -$2.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |